1. Home
  2. BLFS vs ABUS Comparison

BLFS vs ABUS Comparison

Compare BLFS & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BioLife Solutions Inc.

BLFS

BioLife Solutions Inc.

HOLD

Current Price

$23.95

Market Cap

923.5M

Sector

Health Care

ML Signal

HOLD

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$4.35

Market Cap

848.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BLFS
ABUS
Founded
1987
2005
Country
United States
United States
Employees
N/A
19
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
923.5M
848.8M
IPO Year
2013
2008

Fundamental Metrics

Financial Performance
Metric
BLFS
ABUS
Price
$23.95
$4.35
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$32.00
$5.00
AVG Volume (30 Days)
366.8K
1.6M
Earning Date
05-07-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
77.27
55.26
EPS
0.02
0.87
Revenue
$96,214,000.00
$14,083,000.00
Revenue This Year
$19.73
N/A
Revenue Next Year
$17.82
$239.71
P/E Ratio
$1,146.75
$4.80
Revenue Growth
16.97
128.21
52 Week Low
$17.86
$3.04
52 Week High
$29.57
$5.10

Technical Indicators

Market Signals
Indicator
BLFS
ABUS
Relative Strength Index (RSI) 66.34 51.67
Support Level $23.74 $4.17
Resistance Level $26.30 $4.60
Average True Range (ATR) 1.09 0.16
MACD 0.17 -0.00
Stochastic Oscillator 92.62 62.50

Price Performance

Historical Comparison
BLFS
ABUS

About BLFS BioLife Solutions Inc.

BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: